Objective: To characterize the underlying genetic and molecular defects in a consanguineous family with lifelong blood disorder manifested with thrombocytopenia (low platelets count) and anemia. Methods: Genetic linkage analysis, exome sequencing, and functional genomics were carried out to identify and characterize the defective gene. Results: We identified a novel truncation mutation (p.C108*) in chromosome 6 open reading frame 25 (C6orf25) gene in this family. We also showed the p.C108* mutation was responsible for destabilizing the encoded truncated G6B protein. Unlike the truncated form, wild-type G6B expression resulted in enhanced K562 differentiation into megakaryocytes and erythrocytes. C6orf25, also known as G6B, is an effector protein for the key hematopoiesis regulators, Src homology region 2 domain-containing phosphatases SHP-1 and SHP-2. Conclusion: G6B seems to act through an autosomal recessive mode of disease transmission in this family and regarded as the gene responsible for the observed hematological disorder. This inference is well supported further by in vivo evidence where similar outcomes were reported from G6b À/À and SHP1/2 DKO mouse models.
Blood disorders can result from developmental molecular impairments in the bone marrow progenitor cells as a result of abnormal cellular division and/or differentiation. Thrombocytopenia and anemia are two distinctive examples of these blood anomalies. Thrombocytopenia is characterized by low platelets counts that are below normal levels (˂50 000/lL) compared to healthy individuals, whereas anemia is caused by a reduction in hemoglobin contents and/or low red blood cell (RBC) counts (1) (2) (3) (4) (5) . Platelets-producing megakaryocytes (MEGs) and RBCs derive from a common ancestor progenitor cells in a process that is regulated by several transcription factors including GATA binding protein 1 (GATA1) (6) . Genetic defects in GATA1 gene can lead to anemia and/or thrombocytopenia (7) . Defects in other transcription factors such as T-cell acute lymphoblastic leukemia 1 (TAL1), FOG family member 1 (FOG1), and nuclear factor erythroid 2 (NFE2) can also lead to erythroid and megakaryocytic alteration, which manifest in anemia and low platelets count, respectively (8) . Other factors can alter the generation of one lineage over the other; for example, FLI1 proto oncogene (FLI1) prompts MEGs production, whereas Kruppel-like factor 1 (KLF1) prompts RBCs formation (9, 10) . Heritable thrombocytopenia may be transmitted as autosomal dominant, recessive, or X-linked (11) . Certain forms of anemia including thalassemia, sickle cell, and Fanconi anemia are also heritable (12, 13) . Thalassemia and sickle-cell anemia constitute the majority of inherited recessive hemoglobin disorders worldwide (14) . In the Arabs world, hemoglobinopathies are mainly sickle-cell anemia and b-thalassemia, and both are expressed as recessive traits (15) . There are no data available on the incidence of heritable thrombocytopenia among Arab population at the current time.
High consanguinity rates combined with large family size are associated with increased incidence of rare and heritable disorders, with the autosomal recessive forms dominating the transmission of such disorders. A study in 2010 reported 10.4% of the overall world marriages are consanguineous (16) . Marriage between relatives is commonly practiced in the Middle East, exceeding 50% of all marriages for some countries (17) . For some Mediterranean Arab families, this inbreeding practice often unites double first cousins with breading coefficient (F) of 0.125 and that naturally manifests with increased risk of autosomal recessive disorders (18) ; this increase is a direct result from the enrichment of regions of homozygosity (ROH) that are embracing deleterious gene variants.
Using homozygosity mapping and whole exome sequencing, we report the discovery of a defective G6B recessive novel gene in multiply affected siblings from a consanguineous Arab family. All affected members are significantly exhibiting lifelong reduced platelets counts combined with anemia phenotype. We show that a truncation mutation in G6B was responsible for this phenotype, as evidenced by the wild-type G6B expression which enhanced K562 cells differentiation into megakaryocytes and erythrocytes; the truncated form of G6B failed to enhance this differentiation. The schemes undertaken for identifying and characterizing the G6B gene are discussed.
Methods

Enrollment of study participants
Study participants are all adults above the age 21 yr and belong to a consanguineous family of an Arabian origin. All participants agreed and voluntarily joined this study. Clinical history was taken for all members by their family doctor, followed by withdrawal of 8 mL of blood into two EDTA anticoagulated tubes for plasma, RNA, and DNA extractions.
Linkage analysis
High density genotyping approach was performed to identify the locus harboring the disease gene, using Illumina Human OmniExpress bead genotyping array (Illumina Inc., San Diego, CA, USA; n = 730,525 SNP markers). Genotyping was carried out in Dasman Diabetes Institute genome centre, Kuwait. Call rate of 99.9% was used for concordance and quality control (QC) checks, using Illumina GenomeStudio software. Linkage analysis assumed an autosomal recessive model of disease transmission, with 100% penetrance in this consanguineous family. Family-based association test (FBAT) using Golden Helix software was utilized for the analysis (19) . The critical locus from the FBAT analysis was used to guide the shortlisting of candidate genes in the second tier analysis via exome sequencing and analysis.
Whole exome sequencing
For whole exome sequencing was carried out according to Illumina TruSeq Enrichment standardized protocol. Detailed filter settings are given in Tables S1 and S2.
G6B plasmids transient transfection using K562 cells
Human myelogenous leukemia cell line (K562) was obtained from American Type Culture Collection (Rockville, Baltimore, MD, USA). Cells were cultured in suspension using Eagle's Minimum Essential Medium (EMEM) supplemented with 10% fetal bovine serum and penicillin/streptomycin. Both wild-type (full length) and the truncated forms of G6B were cloned into pCMV-6 vector with either FLAG or GFP tags at the c-terminus. For transient transfection assays, 10 9 10 6 K562 cells were used and were transfected with either mock, wild-type, or truncated G6B. Both FLAG and GFP tagged clones were used. Briefly, 24 lg of plasmid DNA were mixed with Lipofectamine 3000 as recommended by the manufacturer (Invitrogen, Carlsbad, CA, USA) and added to the cells in antibiotics-free media. Media was changed after 24 h of transfection, and the cells were grown in complete EMEM media for another 24 h before harvesting for protein analysis.
Platelet vs. erythrocyte-like differentiation of K562 cells
Transiently transfected K562 cells, with the described G6B constructs, were differentiated into platelet-like and erythrocyte-like cells using phorbol 12-myristate13-acetate (PMA) and sodium butyrate (Na-Bu) treatments, respectively, as described (20, 21) with minor modifications. For platelet-like differentiation, K562 (5 9 10 5 cells) were transiently transfected with wild-type G6B, truncated G6B, or empty vector and then were differentiated a RPMI media containing 10% FCS, 1% Pen/Strep, and 16 nM PMA. The differentiation media was changed daily for a period of 6 d. Similarly, for erythrocyte-like generation, the transfected K562 cells were treated a differentiation media containing with 0.6 nM Na-Bu instead of PMA. Cells were harvested at a time course intervals (6 h, days 2, 4, and 6) for mRNA extractions. All differentiation experiments were performed in triplicates. K562 transiently transfected and differentiated in three independent experiments. The transfection efficiencies were normalized to reduce variations within each experiment. Statistical significance was estimated with a one-tailed Student's t-test assuming equal variance, and error is SEM (*P < 0.05).
Results
Clinical summary and microscopic findings
A consanguineous Arabian family ( Fig. 1 ) with nine siblings (two daughters and seven brothers) was investigated in this study. Four of the siblings (II, IV, V, and VII) manifested at early childhood with persisting thrombocytopenia and anemia. The parents are first cousins, with no history of hematological abnormalities. Ages of siblings from oldest (I) to youngest (IX) are 50, 48, 45, 42, 41, 38, 33, 30, and 28 yr, respectively. Interestingly, siblings II and V developed a significant splenomegaly and both happened to have the lowest hemoglobin levels relative to VI and VII.
Hemoglobin levels of the affected participants varied throughout their life ranging between 6 and 10 g/dL. Variable thrombocytopenia was also observed in the affected siblings with platelets counts ranging from 10 000 to 40 000/lL. Apart from bruising, there is no history of major bleeding. White blood cell counts were always normal for all siblings whether affected or not. No history of increased infections or signs of decreased immunity either was reported.
The peripheral blood smears of those affected showed normal white blood cell morphology and confirmed the severe thrombocytopenia compared to the normal siblings. A representative blood smear film image from an affected family member is shown in Figure S1 . The morphology of platelets was within normal except for increased numbers of giant platelets. The red blood cells showed moderate anisopoikilocytosis with tear drop shape. Rare nucleated red blood cells and neutrophil precursors (e.g. myelocytes and metamyelocytes) could also be identified (leukoerythroblastic reaction).
Each affected sibling had multiple bone marrows biopsies, carried out over their life course, with all these showing a dry tap. The biopsies smears were normo-cellular to hypercellular with all three hematopoietic cell lines being well represented. Megakaryocytes were increased in number with focal clustering. Some enlarged megakaryocytes were also identified. A moderate-to-severe reticulin fibrosis was also present. No increase in CD34 + blasts could be demonstrated. The bone marrows and peripheral blood smears were evaluated by independent hematopatholgists, and all determined the phenotype is consistent with myeloproliferative disorder in this family, with features most compatible with myelofibrosis.
Cytogenetic studies showed normal karyotypes. No karyotyping was performed on the bone marrow because of the dry tap. Therapeutic interventions were limited to providing iron and B12/folic acid supplements. Occasional transfusions were given when needed. Treatment with steroids was attempted with the two siblings showing splenomegaly and lower hemoglobin levels; however, this had not led to any improvements.
Linkage analysis and exomes sequencing
Results revealed an FBAT log À10 score = 1.94, with the critical interval minimized to 27.7 Mb DNA stretch on the petite 'P' short arm of chromosome 6, between SNPs rs13195345 and rs1537638, which encompass a region between p22.3 and p21.1 cytogenetic bands. There were more than 500 genes present in this locus, many of which classified among HLA or the autoimmune gene families. As members of both gender were affected and parents had normal platelet and RBC levels, an autosomal recessive mode of inheritance was assumed for analysis. The filter cascade used for ingenuity analysis is shown in Table S1 . The quality of the sequence reads was assessed using Integrative Genomics Viewer Software (IGV; Broad Institute, Cambridge, MA, USA).
Analysis was carried out on exomes from one affected male and his affected sister (II and V, respectively), in addition to an unaffected male (III) from this family, were sequenced, along with 40 exomes from our in-house database of normal unaffected controls. Ingenuity variant analysis software was used for this analysis (see Tables S1 and  S2 for analysis parameters details). List of deleterious variants identified within the critical linkage interval between the SNPs rs13195345 and rs1537638 was cataloged (Table S3) . A total of 2571 genomic deleterious variants were detected in this family. Of the 2571 variants, 44 mapped to the linkage interval on chromosome 6, and only C6orf25 (c.324C>A; p.C108*) was seen in a homozygous state in the two affected siblings. This change was not seen in the unaffected sibling (III) from this family, or in any of the 40 in-house controls. p.C108* according to ingenuity analysis showed an association value of P = 4.71E-07 and an odds ratio of 1485, further confirming the pathogenic effect predicted from this gene alteration. The identified C6orf25 variant (c.324C>A) was assessed further for its clustering (segregation) by examining its genotypes via Sanger sequencing in all eight participating family members (The genotypes were confirmed as homozygous only in the affected siblings, whereas this variant was heterozygous in the mother (father deceased) and unaffected siblings (see Fig. 1 Fig. 2 . c.324C>A corresponds to a truncation nonsense mutation substituting the cysteine codon at position 108 in the encoded peptide with the stop codon TGA (p.C108*). This mutation eliminates the transmembrane domain, in addition to the cytoplasmic domain which encompasses the immunoreceptor tyrosinebased inhibition motif (ITIM) with its two tyrosine residues (Y211 and Y237).
C6orf25 gene, also known as G6B (Ensembl ID: ENSG00000204420), is located in the major histocompatibility complex (MHC) class III region on chromosome 6 and a member of the immunoglobulin (Ig) superfamily. The protein encoded by this gene is a glycosylated cell surface receptor that is bound to the plasma membrane; however, different transcript variants of this gene also encode soluble protein isoforms that can be found in the endoplasmic reticulum and Golgi that can be detected in the blood circulation (22, 23) .
G6B enhances hematopoietic lineage differentiation
The role of wild-type and truncated G6B in the enhancement of megakaryocytes, platelet precursors, or erythrocytes differentiation was evaluated using the human chronic myelogenous leukemia cell line K562, in the presence of PMA or Na-Bu, respectively. At day 6 of K562 differentiation, qrtPCR analyses demonstrated 33-and 320-fold induction of the platelet unique markers CD41 and CD61, respectively, relative to the undifferentiated cells that are transiently transfected with the scrambled (mock) control plasmid; suggesting PMA is sufficient to induce megakaryocyte/platelet differentiation ( Fig. 3A) (24, 25) . Interestingly, K562 PMAtreated cells transfected with wild-type G6B showed a significant stimulation of platelets differentiation. In these cells, the transcription of CD41 and CD61 was 33-and 22.5-fold higher than that of cells transfected with the scrambled (mock) plasmid construct. Further, in these cells, the expression of CD41 and CD61 was highly significant at day 4; implying that G6B enhances early induction of platelets lineage. On the other hand, cells transfected with the truncated G6B revealed statistically insignificant CD41 and CD61 expression (at onefold and twofold, respectively), similar to that seen with the scrambled plasmid transfections, suggesting a residual possible functional role for the endogenous G6B in these cells (Fig. 3A) .
Transfections of K562 cells treated with Na-Bu resulted in distinctive differential expression of markers specific to the erythropoietic lineage. At day 6 and under similar differentiation conditions, the scrambled plasmid-transfected K562 cells showed temperate expressions of erythrocyte markers CD44 and KLF1, with 15-fold and sixfold relative to baseline expression at day 0, respectively ( Fig. 3B) , consistent with a previous report (21) . The same trend and magnitude was also observed in cells expressing the truncated G6B (Fig. 3B) . The wild-type G6B transfection particularly enhanced the erythrocytic genes expression with a substantial relative induction starting at day 4. At day 6, both CD44 and KLF1 relative expressions compared to those of the scramble vector were 11.6-and 8.5-folds higher, respectively, and statistically significant (Fig. 3B) .
Taking together, these results revealed a potential role for G6B in enhancing the differentiation of K562 cells into platelets or erythrocytes, in the presence of PMA or NaBu, respectively. Nevertheless, G6B alone was not sufficient to induce the hematopoietic lineages (data not shown). 
Truncated G6B leads to degradation
To study the effect of the truncation on the mutant G6B protein, both wild-type and truncated forms of the protein were expressed in K562 cells using FLAG-tag pCMV-6 plasmid vector constructs. Western analysis on cell lysates with G6B specific antibodies showed wild-type G6B protein is detectable while the truncated form was absent, suggesting its degradation (Fig. 4A) . Quantitative rtPCR RNA analysis of confirmed transfection by both constructs was equally efficient as shown in Fig. 4B . Both wild-type and truncated forms of G6B showed over 800-fold increase in expression compared to the mock control.
Proteasome inhibitor and GFP tagging stabilize the truncated G6B protein
To test whether G6B protein is degraded by the proteasome or lysosome mechanism, cells expressing either wild-type or truncated G6B were treated with proteasome inhibitor (MG132, 10 lM) and lysosome inhibitor (chloroquine, 100 lM), respectively. Treatment with the proteasome inhibitor did not affect the wild-type, but caused mild stabilization of the truncated form (Fig. 4C) . Treatment with the lysosome inhibitor did not affect the wild-type G6B protein expression and did not cause any stabilization to the truncated form (Fig. 4E) . G6B gene expression for both treatments was similar and was not affected by either treatment (Fig. 4D,F) .
GFP tagged G6B protein was also used to rule out the impact of the tag on the expression of the G6B protein. To our surprise, GFP tagging of the truncated G6B protein had led to stabilization of the truncated form as shown in Fig. 5A . Treating with the proteasome or the lysosome inhibitors did not affect the protein stability for either form as shown in Fig. 5C ,E. G6B gene expression was similar between truncated and wild-type G6B and was not affected by the proteasome or the lysosome inhibitors as shown in Fig. 5B,D,F . Figure 3 The functional role of G6B enhancing hematopoietic lineage differentiation of K562 cells in the presence of PMA or Na-Bu. Transiently transfected cells with wild-type G6B, truncated-G6B mutant, or monk vector treated with (A) PMA to induce platelet generation or (B) Na-BU to induce erythrocytes differentiation showed significant enhancement of platelet differentiation or erythrocyte differentiation. In the absence of inducing molecules, G6B failed to induce the hematopoietic lineages. RNA was collected at different time points, qrtPCR was performed, and results were normalized against GAPDH and expressed as a fold change relative to undifferentiated day 0 cells, (n = 3, *P < 0.05 relative to 6 h incubation with the compound; *P < 0.05 relative to day 6 Flag transfected cells).
Predicted G6B protein structure
Using the SWISS-MODEL Workspace (26), we predicted the protein structure of the wild-type and truncated forms of G6B. As shown in Fig. 6A , the predicted wild-type G6B protein structure contains a number of beta-sheets that forms an organized tertiary structure. The truncated form of G6B is missing in the beta-sheets structure present in the wildtype. On the other hand, tagging of the truncated G6B protein with GFP has caused major changes in its structure that has possibly lead to its stabilization as shown in Fig. 6C ,D.
Discussion
Using linkage analysis and exome sequencing on a consanguineous family with unusual blood disorders manifested with thrombocytopenia and anemia, we have identified a defective novel G6B gene which maps to short arm of chromosome 6 (band 6p21.3). G6B, also known as C6orf25, which localizes to MHCIII locus, between MHC classes I and II (23), is not a well-characterized gene. We have identified a homozygous mutation (c.324C>A) in the G6B gene, only in the affected members of this family, suggesting cosegregation of homozygous c.324C>A with the disease is strong proof that this mutation is causal.
What we know on G6B role in human is primarily its inhibition of platelets aggregation through the interaction with SHP-1 and SHP-2 (27) . Recent mouse knockout data also suggested G6B signals through and play as major regulator of SHP-1 and SHP-2 (28, 29) affecting megakaryocytic development, platelet production, and function. Furthermore, double SHP1/2 conditional knockout mouse models (MPShp1/2 DKO) had in addition to severely reduced platelets production, an additional hematological aberrations, including a 26% reduction in red blood cells and a 4.2-fold increase in white blood cells, highlighting significant defects in hematopoiesis and immunity (28) . SHP1/2 DKO was lethal in this mouse model as observed in the first few weeks of life. In case of our affected family members who are homozygous for the p.C108* mutation, we find it intriguing and question whether exists a redundant mechanism, that is G6B-independent, compensating for their G6B loss of function. While Mazharian and colleagues (29) reported a reduced platelets count in G6b-B-deficient mice model, there was no information on erythrocytes production, and we are uncertain if such phenotype was documented in their studies.
G6B encodes a putative cell surface immunoglobulin (Ig) superfamily membrane receptor with a transmembrane segment, and a cytoplasmic tyrosine-based inhibitory motif (ITIM) with two tyrosine residues (30) . ITIMs are known to interact with Src homolog 2 (SH2) domain-containing protein tyrosine phosphatases (PTPs) such as SHP-1 and SHP-2. Human SHP1 and SHP2 are encoded by PTPN6 and PTPN11 genes, respectively (31) . Upon activation of the membrane-bound G6B, SHP-1 and/or SHP-2 are recruited to negatively regulate the activation signal via a dephosphorylation mechanism (30, 31) .
The phosphorylation of G6B is also under the control of LYN, a member of the Src family kinases (SFKs). LYN is one of the eight kinases belonging to the SFKs family (32) with a known inhibitory role in the myeloid lineage proliferation and is physically associated with membrane receptors that lack their own catalytic motifs and hence act as intracellular signaling transducer (32, 33) . LYN is a major player in cell cycle signaling in B-cells. The activation of immunoglobulin receptors on these cells trigger their entry into G1 phase which is required in cells division (34) . Upon phosphorylation of tyrosine residues within the ITIM of receptor proteins by LYN (e.g. G6B), other kinases like spleen tyrosine kinase (SYK), phospholipase Cc2 (PLCc2), and phosphatidyl inositol-3 kinase (PI3K) are also recruited as part of the activation cascade (35, 36) . Only scarce human LYN data is available in current literature, and most of the knowledge on this kinase is derived from mice studies. LYN-deficient mice display a spectrum of phenotypes including splenomegaly, and several types of monocyte and macrophage tumors (32); splenomegaly was one of the clinical complications that were reported in the family studied here, which is consistent with the mouse studies. LYN signaling cascade triggers downstream effects including cellular proliferation and differentiation into a myeloid precursor of megakaryocyte and erythroblast lineages which subsequently lead to the formation of platelets and erythrocytes, respectively (37) .
Both megakaryocytes and erythrocytes are generated through a late differentiation event from a common precursor from hematopoietic progenitor cells (HPCs). Several Figure 5 Expression of GFP tagged wild-type and mutant G6B. (A) Wild-type and truncated GFP forms of G6B transfected in K562 showing the stabilization of the truncated form of G6B in untreated K562 cells as well as cells treated with (C) proteasome inhibitor (MG132, 10 lM) or (E) lysosome inhibitor (chloroquine, 100 lM). Truncated form of G6B was stabilized by the GFP tagging under various treatments (B, D, and F). Transfection efficiency of the wild-type and the truncated form of G6B is measured at the mRNA level. No significant difference was observed at the mRNA level between wild-type and truncated G6B. Experiments were performed at n = 3.
transcription factors are shared in this differentiation pathway including GATA1, GATA2, NFE1, NFE2, and FOG1 (38) . We hypothesize that anemia and thrombocytopenia phenotypes observed in the affected members of this family are a consequence of expressing a nonfunctional G6B protein and further propose a pathological mechanisms that is independent from the above regulating genes. This is supported by our PMA-and Na-Bu-driven differentiation in the presence of the wild-type or mutant G6B (Fig. 3A,B) . It is reasonable to speculate that, in case of our family, this whole cascade is interrupted in case of the affected family members, who likely expressing an unstable mutated G6B protein product instead of the native G6B protein; this speculation is suggested by the western analysis results shown in Fig. 4 ; however, this needs an independent confirmation using platelets from the affected family members. Future investigations on G6B using cellular and mouse G6B KO biological systems will be essential to dissect this gene's molecular mechanism in humans and further delineate its exact role in anemia and thrombocytopenia pathogenesis.
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